Insiders Travere Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.26 ^USD	-2.41%		-8.04%	-41.49%

Apr. 24	EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment	MT
Apr. 24	Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization	MT

AnaptysBio Names John Orwin as Board Chairman	23-09-18	MT
Insider Sell: Travere Therapeutics	23-01-26	MT
Insider Sell: Travere Therapeutics	23-01-06	MT
Travere Therapeutics Names Chris Cline CFO	22-04-20	MT
Insider Sell: Travere Therapeutics	22-01-12	MT
Insider Sell: Travere Therapeutics	22-01-12	MT
Travere Therapeutics, Inc. Announces Executive Changes	22-01-06	CI
Travere Therapeutics Names Jula Inrig Chief Medical Officer	22-01-04	MT
Travere Therapeutics, Inc. Appoints Jula Inrig, M.D., as Chief Medical Officer	22-01-04	CI
Insider Sell: Travere Therapeutics	21-11-09	MT
Insider Sell: Travere Therapeutics	21-11-03	MT
Travere Therapeutics : Chief Medical Officer to Shift to Adviser Role at Yearend	21-10-12	MT
Travere Therapeutics, Inc. Announces Executive Changes	21-10-12	CI
Insider Sell: Travere Therapeutics	21-10-08	MT
Travere Therapeutics, Inc. Announces Management Changes	21-09-17	CI
Travere Therapeutics : Appoints Kaiser Foundation Executive Ruth Williams-Brinkley to Board	21-09-14	MT
Travere Therapeutics, Inc. Appoints Ruth Williams-Brinkley to its Board of Directors	21-09-14	CI
Insider Trends: Insider Extends 90-Day Selling Trend at Travere Therapeutics	21-06-03	MT
Insider Trends: Travere Therapeutics Insider Sale Scales Back 90-Days of Buys	21-02-09	MT
Insider Trends: 90-Days of Insider Buying at Travere Therapeutics Interrupted with Share Sale	21-02-09	MT

No results for this search